10x Genomics Files 8-K on Financials
Ticker: TXG · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1770787
| Field | Detail |
|---|---|
| Company | 10x Genomics, Inc. (TXG) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
10x Genomics dropped an 8-K on Jan 12th covering financials - check it for the deets.
AI Summary
On January 12, 2025, 10x Genomics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing provides an update on 10x Genomics' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- 10x Genomics, Inc. (company) — Registrant
- January 12, 2025 (date) — Date of earliest event reported
- 6230 Stoneridge Mall Road (address) — Registrant's principal executive offices
- Pleasanton, California (location) — Registrant's principal executive offices
- 94588 (zip_code) — Registrant's principal executive offices
- (925) 401-7300 (phone_number) — Registrant's principal executive offices
FAQ
What specific financial information is being reported in this 8-K filing?
The provided excerpt indicates the filing concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail specific financial figures.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is January 12, 2025.
What is the principal executive office address for 10x Genomics, Inc.?
The principal executive office address is 6230 Stoneridge Mall Road, Pleasanton, California 94588.
What is the telephone number for 10x Genomics, Inc.'s principal executive offices?
The telephone number is (925) 401-7300.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-13 08:49:43
Key Financial Figures
- $0.00001 — tered Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market
Filing Documents
- txg-20250112.htm (8-K) — 27KB
- ex-991_2025x01x12.htm (EX-99.1) — 18KB
- a10x_logoxhorizontalxfullc.jpg (GRAPHIC) — 152KB
- txg-20250112_g1.jpg (GRAPHIC) — 223KB
- 0001770787-25-000003.txt ( ) — 885KB
- txg-20250112.xsd (EX-101.SCH) — 2KB
- txg-20250112_lab.xml (EX-101.LAB) — 21KB
- txg-20250112_pre.xml (EX-101.PRE) — 12KB
- txg-20250112_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 12, 2025, 10x Genomics, Inc. issued a press release announcing preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing..
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibits 99.1 Press Release dated January 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 10x Genomics, Inc. By: /s/ Eric S. Whitaker Name: Eric S. Whitaker Title: Chief Legal Officer Date: January 13, 2025